🎉 M&A multiples are live!
Check it out!

Perspective Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Perspective Therapeutics and similar public comparables like Senseonics Holdings, InfuSystem, and SmartVest.

Perspective Therapeutics Overview

About Perspective Therapeutics

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.


Founded

1983

HQ

United States of America
Employees

119

Financials

LTM Revenue $1.3M

LTM EBITDA -$68.7M

EV

-$88.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Perspective Therapeutics Financials

Perspective Therapeutics has a last 12-month revenue of $1.3M and a last 12-month EBITDA of -$68.7M.

In the most recent fiscal year, Perspective Therapeutics achieved revenue of n/a and an EBITDA of -$39.1M.

Perspective Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Perspective Therapeutics valuation multiples based on analyst estimates

Perspective Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $1.4M XXX XXX XXX
Gross Profit $4.6M $0.8M XXX XXX XXX
Gross Margin Infinity% 57% XXX XXX XXX
EBITDA -$39.1M -$62.5M XXX XXX XXX
EBITDA Margin -Infinity% -4395% XXX XXX XXX
Net Profit -$7.3M -$7.3M XXX XXX XXX
Net Margin -Infinity% -516% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Perspective Therapeutics Stock Performance

As of March 17, 2025, Perspective Therapeutics's stock price is $3.

Perspective Therapeutics has current market cap of $175M, and EV of -$88.5M.

See Perspective Therapeutics trading valuation data

Perspective Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$88.5M $175M XXX XXX XXX XXX $-0.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Perspective Therapeutics Valuation Multiples

As of March 17, 2025, Perspective Therapeutics has market cap of $175M and EV of -$88.5M.

Perspective Therapeutics's trades at -68.9x LTM EV/Revenue multiple, and 1.3x LTM EBITDA.

Analysts estimate Perspective Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Perspective Therapeutics and 10K+ public comps

Perspective Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$88.5M XXX XXX XXX
EV/Revenue -62.3x XXX XXX XXX
EV/EBITDA 1.4x XXX XXX XXX
P/E -3.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Perspective Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Perspective Therapeutics Valuation Multiples

Perspective Therapeutics's NTM/LTM revenue growth is -42%

Perspective Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Perspective Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Perspective Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Perspective Therapeutics and other 10K+ public comps

Perspective Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -4395% XXX XXX XXX XXX
EBITDA Growth 60% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -4437% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Perspective Therapeutics Public Comps

See public comps and valuation multiples for Medical Devices and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Myomo XXX XXX XXX XXX XXX XXX
Senseonics Holdings XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Perspective Therapeutics M&A and Investment Activity

Perspective Therapeutics acquired  XXX companies to date.

Last acquisition by Perspective Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Perspective Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Perspective Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Perspective Therapeutics

When was Perspective Therapeutics founded? Perspective Therapeutics was founded in 1983.
Where is Perspective Therapeutics headquartered? Perspective Therapeutics is headquartered in United States of America.
How many employees does Perspective Therapeutics have? As of today, Perspective Therapeutics has 119 employees.
Who is the CEO of Perspective Therapeutics? Perspective Therapeutics's CEO is Mr. Johan M. Spoor.
Is Perspective Therapeutics publicy listed? Yes, Perspective Therapeutics is a public company listed on ASE.
What is the stock symbol of Perspective Therapeutics? Perspective Therapeutics trades under CATX ticker.
When did Perspective Therapeutics go public? Perspective Therapeutics went public in 2005.
Who are competitors of Perspective Therapeutics? Similar companies to Perspective Therapeutics include e.g. Philips, SmartVest, InfuSystem, Myomo.
What is the current market cap of Perspective Therapeutics? Perspective Therapeutics's current market cap is $175M
What is the current revenue of Perspective Therapeutics? Perspective Therapeutics's last 12-month revenue is $1.3M.
What is the current EBITDA of Perspective Therapeutics? Perspective Therapeutics's last 12-month EBITDA is -$68.7M.
What is the current EV/Revenue multiple of Perspective Therapeutics? Current revenue multiple of Perspective Therapeutics is -68.9x.
What is the current EV/EBITDA multiple of Perspective Therapeutics? Current EBITDA multiple of Perspective Therapeutics is 1.3x.
Is Perspective Therapeutics profitable? Yes, Perspective Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.